LATEST RESOURCES FOR DOWNLOAD

LATEST EXPERT VIDEOS

Jorge Castillo discusses the relative efficacy and safety of BTK inhibitors with or without BCL2 inhibitors in Waldenström’s macroglobulinemia (WM), highlights important prognostic molecular markers in untreated patients, and reveals new insights into the biology of the disease. He also explores novel therapeutic targets that may shape the future of WM treatment.

Matthew S. Davids provides insights into the potential of the new drug class of protein degraders in CLL treatment and discusses recently identified biomarkers that are prognostic or predictive in the era of targeted therapy. He also evaluates the performance of BTK-inhibitor-based treatments in high-risk CLL or after prior exposure to targeted agents and explores strategies to overcome real-world barriers to guideline- and evidence-based care in CLL.